Preferred Label : Zunsemetinib;
NCIt definition : An orally bioavailable, small molecule inhibitor of mitogen-activated protein (MAP)
kinase-activated protein kinase 2 (MAPKAPK2; MK2), with potential anti-inflammatory
activity. Upon oral administration, zunsemetinib targets and binds to the p38MAPK-MK2
complex, thereby inhibiting the p38MAPK phosphorylation and activation of MK2. This
inhibits p38MAPK/MK2-mediated inflammatory signaling pathway. This may result in the
inhibition of the production of proinflammatory cytokines, including tumor necrosis
factor-alpha (TNF-alpha), interleukin (IL)-1-alpha, IL-1-beta and IL-6.;
UNII : AX2VWG0ZCR;
CAS number : 1640282-42-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1640282-42-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : CDD-450; ATI-450; ATI 450;
NCI Metathesaurus CUI : CL1770950;
Origin ID : C182621;
UMLS CUI : C5667672;
Semantic type(s)
- concept_is_in_subset
- has_target
